-
New research indicates that early initiation of antiretroviral treatment in people infected with HIV prevents them from transmitting the virus to their partners.
-
In this issue: FDA issues multiple drug safety alerts; ARBs and cancer risk; and FDA actions.
-
The authors performed a descriptive analysis of all cases of desquamative inflammatory vaginitis (DIV), defined as symptomatic vaginitis (discharge, dyspareunia, pruritus, burning, or irritation) associated with vaginal inflammation (such as focal or linear erosions), a vaginal pH higher than 4.5, and saline microscopy showing an increase in parabasal and inflammatory cells in the absence of an infectious etiology (such as trichomonas, candida, or bacterial vaginosis).
-
Understanding sexual pain remains limited. With multiple etiologies and lack of evidence-based outcomes research, future investigations should focus on evaluating the intimacy of the couple, the partner relationship, and biomedical sources of pain such as the pelvic floor muscles.
-
While adolescents are at risk for HIV, many forego testing. This lack of testing is a major public health concern, as more than 50% of HIV-infected adolescents do not know their infection status.
-
Thumbing through your inbox charts, you see your next patient is a 19-year-old who began use of oral contraceptives (OCs) about six months ago. When you talk with her in the examination room, however, you find that she has discontinued use of the Pill after she began to gain weight.
-
What will it take to drive down the number of chlamydia infections in young women? While routine chlamydia screening is recommended for all sexually active females age 24 years and younger, only about half (49.9%) were screened during 2008-09, according to data collected in more than 1,000 U.S. health plans.
-
For four decades, safety-net providers such as community health centers have turned to the National Health Service Corps (NHSC) for help with maintaining a well-trained and credentialed workforce.
-
One woman in five develops a urinary tract infection (UTI) during her lifetime, according to the National Institute of Diabetes and Digestive and Kidney Diseases.
-
Add another human papillomavirus (HPV) test to the clinical arsenal. The Food and Drug Administration (FDA) has approved the Roche cobas HPV Test.